Client and program characteristics associated with wait time to substance abuse treatment entry

American Journal of Drug and Alcohol Abuse

Volumn 39, Issue 1, 2013, Pages 61-68

  Andrews, Christina M ^a   Shin, Hee Choon ^b   Marsh, Jeanne C ^a   Cao, Dingcai ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Access; Substance abuse treatment; Treatment entry; Wait time

Indexed keywords

METHADONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; CRIMINAL JUSTICE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; EUROPEAN AMERICAN; FEMALE; HEALTH CARE DELIVERY; HEALTH PROGRAM; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE;

ADULT; AFRICAN AMERICANS; AMBULATORY CARE; CRIMINAL LAW; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; METHADONE; OUTPATIENTS; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; WAITING LISTS;

EID: 84872018303     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2012.694515     Document Type: Article

References (38)

1. Substance Abuse and Mental Health Services Administration, Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41 (HHS Publication No. (SMA) 11-4658). Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011
2. Claus RE, Kindleberger LR. Engaging substance abusers after centralized assessment: Predictors of treatment entry and dropout. J Psychoactive Drugs 2002; 34(1):25-31
3. Festinger DS, Lamb RJ, Kountz MR, Kirby KC, Marlowe D. Pretreatment dropout as a function of treatment delay and client variables. Addict Behav 1995; 20(1):111-115
4. Appel PW, Ellison AA, Jansky HK, Oldak R. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: Opinions of drug injecting street outreach clients and other system stakeholders. Am J Drug Alcohol Abuse 2004; 30(1):129-153
5. Farabee D, Leukefeld CG, Hays L. Accessing drug-abuse treatment: Perceptions of out-of-treatment injectors. J Drug Issues 1998; 28(2):381-394
6. Pollini RA,McCall L, Mehta SH, Vlahov D, Strathdee SA. Nonfatal overdose and subsequent drug treatment among injection drug users. Drug Alcohol Depend 2006; 83(2):104-110
7. Hoffman KA, Ford JH, Choi D, Gustafson DH, McCarty D. Replication and sustainability of improved access and retention within the network for the improvement of addiction treatment. Drug Alcohol Depend 2008; 98:63-69
8. Alterman AI, Bedrick J, Howden D, Maany I. Reducing waiting time for substance abuse treatment does not reduce attrition. J Subst Abuse Treat 1994; 6(3):325-332
9. Donovan DM, Rosengren DB, Downey L, Cox GB, Sloan KL. Attrition prevention with individuals awaiting publicly funded drug treatment. Addiction 2001; 96(8):1149-1160
10. Stasiewicz PR, Stalker R. Brief report a comparison of three "interventions" on pretreatment dropout rates in an outpatient substance abuse clinic. Addict Behav 1999; 24(4):579-582
11. Aday LA, Andersen RM. A framework for the study of access to medical care. Health Serv Res 1974; 9(3):208-220
12. Jackson KR, Booth PG, McGuire J, Salmon P. Predictors of starting and remaining in treatment at an alcohol clinic. J Subst Use 2006; 11(2):89-100
13. Maddux JF, Desmond DP, Esquivel M. Rapid admission and retention on methadone. Am J Drug Alcohol Abuse 1995; 21(4):533-547
14. Carr CJ, Xu J, Redko C, Lane DT, Rapp RC, Goris J, Carlson RG. Individual and system influences on waiting time for substance abuse treatment. J Subst Abuse Treat 2008; 34(2):192-201
15. Downey L, Rosengren DB, Donovan DM. Gender, waitlists, and outcomes for public-sector drug treatment. J Subst Abuse Treat 2003; 25(1):19-28
16. Arfken C, Klein C, di Menza S, Schuster C. Gender differences in problem severity at assessment and treatment retention. J Subst Abuse Treat 2001; 20:53-57
17. Grella C, Scott CK, Foss M, Joshi V, Hser Y. Gender differences in drug treatment outcomes among participants in the Chicago target cities studies. Eval Program Plann 2003; 26(3):297-310
18. Grella C. Services of perinatal women with substance abuse and mental health disorders: The unmet need. J Psychoactive Drugs 1997; 4:319-343
19. Marsh JC, Miller NA. Female clients in substance abuse treatment. Int J Addict 1985; 20(6-7):995-1019
20. Marsh JC, D'Aunno TA, Smith BD. Increasing access and providing social services to improve drug abuse treatment for women with children. Addiction 2000; 95(8):1237-1247
21. Amaro H, Nieves R, Johannes SW, Cabeza ZL. Substance abuse treatment: Critical issues and challenges in the treatment of Latina women. Hispanic J Behav Sci 1999; 21(3):266-282
22. McCaughrin W, Howard D. Variation in access to outpatient substance abuse treatment: Organizational factors and conceptual issues. J Subst Abuse 1996; 8:403-415
23. Friedmann PD, Lemon SC, Stein MD, D'Aunno TA. Accessibility of addiction treatment: Results from a national survey of outpatient substance abuse treatment organizations. Health Serv Res 2003; 38(3):887-903
24. Gryczynski J, Schwartz RP, O'Grady K, Jaffe J. Treatment entry among individuals on a waiting list for methadone maintenance. Am J Drug Alcohol Abuse 2009; 35(5):290-294
25. Gerstein DR, Datta AR, Ingels JS, Johnson RA, Rasinski KA, Schildlaus S, Talley K, Jordan K, Phillips DB, Anderson DW, Condelli WG, Collins JS. Final Report. NTIES: National Treatment Improvement Evaluation Study. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 1995
26. Gerstein DR, Johnson RA. Nonresponse and selection bias in treatment follow-up studies. Subst Use Misuse 2000; 35:971-1014
27. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: Wiley & Sons, 1987
28. Schaefer JL. Analysis of Incomplete Multivariate Data. New York, NY: Chapman & Hall, 1997
29. Grant BF. Barriers to alcoholism treatment: Reasons for not seeking treatment in a general population survey. J Stud Alcohol 1997; 58:365-371
30. Schmidt L, Tam T, Larson MJ. Understanding the Substance Abuse Treatment Gap. Washington, DC: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (SAMHSA), 2007
31. Wu LT, Kouzis AC, Schlenger WE. Substance use, dependence, and service utilization among the US uninsured nonelderly population. Am J Pub Health 2003; 93:2079-2085
32. Jacobsen JO, Robinson PL, Bluthenthal RN. Racial disparities in completion rates from publicly funded alcohol treatment: Economic resources explain more than demographics and addiction severity. Health Serv Res 2007; 42:773-794
33. Brown BS, Hickey JE, Chung AS, Craig RD, Jaffe JH. The functioning of individuals on a drug abuse treatment waiting list. Am J Drug Alcohol Abuse 1989; 15:261-274
34. Weisner C, Matzger H. A prospective study of the factors influencing entry to alcohol and drug treatment. J Behav Health Serv Res 2002; 29(2):126-137
35. Perron B, Bright C. The influence of legal coercion on dropout from substance abuse treatment: Results from a national survey. Drug Alcohol Depend 2008; 92:123-131
36. National Institutes of Health. National consensus development panel on effective medical treatment of opiate addiction. Effective medical treatment of opiate addiction. J Am Med Assoc 1998; 280(22):1936-1943
37. Peterson JA, Schwartz RP, Mitchell SG, Reisinger HS, Kelly SM, O'Grady KE. Brown BS Agar MH. Why don't out-oftreatment individuals enter methadone treatment programs? Int J Drug Policy 2010; 21(1):36-42
38. Buck JA. The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affair 2011; 30(8):1402-1410s